Table 2 Recipient characteristics at the time of lung transplantation
Allo-HSCT cohort (n = 19) | Matched controls (n = 38) | p value | |
|---|---|---|---|
Age, years | |||
Median [IQR] | 39.2 [29.6–48.7] | 35.3 [25.9–54.3] | 0.906 |
Sex, % male | 47.40% | 63.20% | 0.273 |
BMI | 19.7 ± 3.2 | 22.0 ± 4.9 | 0.07 |
Time on waiting list, months | |||
Median [IQR] | 2.1 [1.0–4.9] | 1.8 [0.8–6.2] | 0.488 |
Indication for LTx | LONIPCs of allo-HSCT—100% | CF—60.5% (23) | N/A |
ILD—28.9% (11) | |||
PAH—5.3% (2) | |||
COPD—5.3% (2) | |||
Waiting listing priority | |||
Status 1 | 21.1% (4) | 13.2% (5) | 0.463 |
Status 2 | 42.1% (8) | 57.9% (22) | 0.279 |
Status 3 | 36.8% (7) | 29.0% (11) | 0.56 |
Mechanical or ECLS bridging to LTx | 26.3% (5) | 10.5% (4) | 0.143 |
Double lung transplant | 100% | 100% | 1 |
Donor-recipient crossmatch1 | |||
Standard IS risk | 89.5% (17) | 94.7% (36) | 0.855 |
Increased IS risk | 10.5% (2) | 5.3% (2) | |
CMV status | |||
D−ve/R−ve | 36.8% (7) | 31.6% (12) | 0.769 |
D−ve/R+ve | 31.6% (6) | 34.2% (13) | > 0.99 |
D+ve/R−ve | 15.8% (3) | 21.1% (8) | 0.735 |
D+ve/R+ve | 15.8% (3) | 13.2% (5) | > 0.99 |
Hypogammaglobulinemia | |||
Pre LTx IgG level, g/L | 11.2 ± 4.9 | Not assessed | N/A |
Pre LTx IVIg replacement | 21.1% (4) | 0% | 0.007 |
Recipient co-morbidities | |||
Ex-smoker | 26.3% (5) | 26.3% (10) | > 0.99 |
Diabetes | 21.1% (4) | 29.0% (11) | 0.751 |
GERD | 10.5% (2) | 34.5% (20) | 0.077 |
Hypertension | 15.8% (3) | 13.2% (5) | > 0.99 |
Pre-LTx respiratory pathogen history | |||
Aspergillus | 42.1% (8) | 34.2% (13) | 0.575 |
Pseudomonas | 31.6% (6) | 50% (19) | 0.26 |
NTM | 26.3% (5) | 7.9% (3) | 0.102 |
Burkholderia2 | 0% (0) | 7.9% (3) | 0.544 |
Recipient BAL at LTx | |||
Category 1 pathogens | 26.3% (5) | 36.8% (14) | 0.555 |
Category 2 pathogens | 5.3% (1) | 18.4% (7) | 0.247 |
Category 1 or 2 | 31.6%% (6) | 39.5% (15) | 0.772 |